What is Insulet?
Headquartered in Massachusetts, Insulet Corporation is an innovative medical device company focused on simplifying the lives of individuals with diabetes and other chronic conditions through its proprietary Omnipod Insulin Management System. This unique wearable device offers a needle-free alternative for insulin delivery, providing up to three days of continuous administration. Beyond diabetes, Insulet is strategically leveraging its Omnipod technology platform to address drug delivery needs in other therapeutic areas, demonstrating a commitment to broad healthcare solutions.
How much funding has Insulet raised?
Insulet has raised a total of $175.5M across 2 funding rounds:
Stock Offering
$115.5M
Debt
$60M
Stock Issuance/Offering (2007): $115.5M, investors not publicly disclosed
Debt (2009): $60M led by Deerfield Management Company
Key Investors in Insulet
Deerfield Management Company
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
What's next for Insulet?
With the recent influx of major strategic investment, Insulet is poised for accelerated development and market penetration. The substantial capital infusion, reflected in the total funding of $175.5M, suggests a company in a scaling phase, likely focusing on expanding its product reach, enhancing manufacturing capabilities, and potentially exploring new therapeutic applications for its innovative delivery system. This strategic backing indicates strong investor confidence in Insulet's long-term vision and its capacity to disrupt traditional treatment paradigms.
See full Insulet company page
